Radiosynthesis and validation of [5-cyano-N-(4-(4-[11 C]methylpiperazin-1-yl)-2-(piperidin-1-yl)phenyl) furan-2-carboxamide] ([11 C]CPPC), a PET radiotracer for imaging CSF1R, a microglia-specific marker.
William B MathewsYunkou WuAndrew G HortiRavi NaikAndrew W HallDaniel P HoltRobert F DannalsPublished in: Journal of labelled compounds & radiopharmaceuticals (2019)
In this practitioner protocol, the radiochemical synthesis of [11 C]CPPC is described in detail, and a quality control summary of three validation productions is presented. The results indicate that the radiotracer product can be produced in good radiochemical yield (> 60 mCi (2.22 GBq) at end-of-synthesis (EOS)), at high specific activity (molar activity > 11,435 mCi/μmole (423 GBq/μmole) at EOS) and high chemical and radiochemical purity. The entire production conforms to current Good Manufacturing Practice (cGMP) requirements. The final product is formulated as a sterile, pyrogen-free solution suitable for human injection.
Keyphrases
- pet imaging
- quality control
- mild cognitive impairment
- endothelial cells
- primary care
- randomized controlled trial
- nitric oxide
- positron emission tomography
- high resolution
- pet ct
- induced pluripotent stem cells
- neuropathic pain
- ultrasound guided
- spinal cord injury
- photodynamic therapy
- fluorescence imaging
- cerebrospinal fluid